"The U.S. Food and Drug Administration recently approved Oralair to treat allergic rhinitis (hay fever) with or without conjunctivitis (eye inflammation) that is induced by certain grass pollens in people ages 10 through 65 years. Oralair is the f"...
There are no data available on the effects of acute or chronic overdosage with NASONEX (mometasone furoate (nasal spray)) Nasal Spray 50 mcg. Because of low systemic bioavailability, and an absence of acute drug-related systemic findings in clinical studies, overdose is unlikely to require any therapy other than observation. Intranasal administration of 1600 mcg (4 times the recommended dose of NASONEX (mometasone furoate (nasal spray)) Nasal Spray 50 mcg for the treatment of nasal polyps in patients 18 years of age and older) daily for 29 days, to healthy human volunteers, showed no increased incidence of adverse events. Single intranasal doses up to 4000 mcg and oral inhalation doses up to 8000 mcg have been studied in human volunteers with no adverse effects reported. Chronic over dosage with any corticosteroid may result in signs or symptoms of hypercorticism [see WARNINGS AND PRECAUTIONS]. Acute overdosage with this dosage form is unlikely since one bottle of NASONEX (mometasone furoate (nasal spray)) Nasal Spray 50 mcg contains approximately 8500 mcg of mometasone furoate.
NASONEX (mometasone furoate (nasal spray)) Nasal Spray is contraindieated in patients with known hypersensitivity to mometasone furoate or any of its ingredients.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/7/2011
Additional Nasonex Information
Nasonex - User Reviews
Nasonex User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.